Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 06; 16(6):1030-1041.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Chemoradiotherapy
ErbB Receptors
Humans
Lung Neoplasms
Neoplasm Recurrence, Local
Retrospective Studies
authors with profiles
Ravi Salgia